We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Boehringer Ingelheim Buys Zantac Rights for $509.5 Million
Boehringer Ingelheim Buys Zantac Rights for $509.5 Million
October 13, 2006
Boehringer Ingelheim Pharmaceuticals said it is buying the U.S. rights to the OTC antacid Zantac from Pfizer for $509.5 million in cash.